Tormere Analytics
OverviewStock ResearchPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Pricing
Privacy PolicyTerms of Service

EYPT

$4.25-2.07%

EyePoint, Inc.

Market Cap
$401M
Sector
Health Care
Industry
Pharmaceuticals
Beta
1.57
5yr monthly vs SPY
Price Chart
Loading…

Signals

Insider Velocity
46.1x
buying
Congress
—
recent trades
Short Volume
43%
W/W -8.3pp

Market & Alt Data

News
15
recent articles
Activist
—
none active
Analyst Consensus
Buy
19 analysts

Buy Activity

Buy Velocity Score
46.13x
Current Rate (90d)
117.78/mo
Baseline Rate
6.12/mo
Unique Buyers (90d)
1

Sell Activity

Sell Velocity Score
4.35x
Sell Rate (90d)
54.17/mo
Sell Baseline
29.84/mo
Unique Sellers (90d)
1
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-08-182026-08-18Zaderej Karen L.DirectorPurchase10.6K$4.93$52K49.1KView
2026-06-302026-07-02Ribeiro RamiroChief Medical OfficerSale4,875$15.01$73K0View
2026-04-172026-04-20Ribeiro RamiroChief Medical OfficerSale2,437$15.00$37K0View
2026-03-162026-03-16Duker Jay S.Director & President and CEOPurchase1,500$13.15$20K100.7KView
2026-03-042026-03-05Ribeiro RamiroChief Medical OfficerSale2,438$17.87$44K0View
1–5 of 6
1 / 2

Recent News

EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
SeekingAlpha · 2026-09-09
Street Calls of the Week
Yahoo · 2026-09-06
EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO
Yahoo · 2026-09-04
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls
Yahoo · 2026-09-02

Informational purposes only, not investment advice.

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, GitLab, GLOBAL FOUNDRIES, Martin Marietta Materials, Rocket Lab USA, Strategy, Toast, Tower Semiconductor, and More
Yahoo · 2026-09-02
This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Benzinga · 2026-09-02
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
Yahoo · 2026-09-02
TD Cowen Downgrades EyePoint to Hold, Lowers Price Target to $4
Benzinga · 2026-09-02
EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward
SeekingAlpha · 2026-08-27
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Benzinga · 2026-08-25
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
SeekingAlpha · 2026-08-19
EyePoint: Still A Sell After Phase 3 Crash
SeekingAlpha · 2026-08-19
EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says
Yahoo Finance · 2026-08-18
EyePoint’s Duravyu falls short to Eylea in Phase III trial
Yahoo Finance · 2026-08-18
EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’
Yahoo Finance · 2026-08-18

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →
Pipeline
Phase 4
5 active trials · readout 2026-10